Addiction

U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures

U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures U.S. Patent for…

2 years ago

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven…

2 years ago

Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference

CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today…

2 years ago

Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)…

2 years ago

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and…

2 years ago

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders so patients #DontMissAnotherMoment…

2 years ago

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

2 years ago

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing…

2 years ago

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic…

2 years ago

Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803

KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"),…

2 years ago